We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · June 13, 2019

Oral Semaglutide vs Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4)

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial
Lancet 2019 Jun 08;[EPub Ahead of Print], R Pratley, A Amod, ST Hoff, et al

Further Reading